A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review

The echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion is almost mutually exclusive to epidermal growth factor receptor (EGFR) or K-RAS mutation in non-small cell lung cancer (NSCLC), and it is extremely rare for patients to exhibit both mutations. The present study reported the case of a 71-year-old female diagnosed with adenocarcinoma, exhibiting mutations in EGFR and EML4-ALK. The present study treated this patient with EGFR-TK inhibitors, as the first line therapy, and gefitinib therapy revealed a good response until now. In addition, previously reported cases and associated literature were reviewed. The present study provided a greater understanding of the molecular biology and optimal treatment for patients with NSCLC with >1 driver mutation.